The effects of berberine on blood lipids: A systemic review and meta-analysis of randomized controlled trials

Planta Medica

Volumn 79, Issue 6, 2013, Pages 437-446

  Dong, Hui ^a   Zhao, Yan ^a   Zhao, Li ^a   Lu, Fuer ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

berberine; clinical trials; lipid; meta analysis; randomized controlled trials; systematic review

Indexed keywords

BERBERINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ABSENCE OF SIDE EFFECTS; ARTICLE; BITTER TASTE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW;

ADULT; BERBERINE; CHOLESTEROL; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84876679315     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1328321     Document Type: Article

References (40)

1. Ford E. S., Li C., Pearson W. S., Zhao G., Mokdad A. H. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol: 2010; 140 226 235
2. Ross R., Harker L. Hyperlipidemia and atherosclerosis. Science: 1976; 193 1094 1100
3. Wang Y. R., Alexander G. C., Meltzer D. O. Screening and treatment of hypercholesterolemia for prevention of coronary heart disease. Manag Care Interface: 2006; 19 25 29 (Pubitemid 43132599)
4. Lewis A., Segal A. Hyperlipidemia and primary prevention of stroke: does risk factor identification and reduction really work? Curr Atheroscler Rep: 2010; 12 225 229
5. Iughetti L., Bruzzi P., Predieri B. Evaluation and management of hyperlipidemia in children and adolescents. Curr Opin Pediatr: 2010; 22 485 493
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA: 2001; 285 2486 2497
7. Staels B., Schoonjans K., Fruchart J. C., Auwerx J. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Biochimie: 1997; 79 95 99 (Pubitemid 27290348)
8. Fruchart J. C., Brewer H. B. Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol: 1998; 81 912 917 (Pubitemid 28204644)
9. Abourbih S., Filion K. B., Joseph L., Schiffrin E. L., Rinfret S., Poirier P., Pilote L., Genest J., Eisenberg M. J. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med: 2009; 122 962 e1-e8
10. de Denus S., Spinler S. A., Miller K., Peterson A. M. Statins and liver toxicity: a meta-analysis. Pharmacotherapy: 2004; 24 584 591 (Pubitemid 38585952)
11. Bates E. R. Review: limited evidence suggests that statins are safe in patients with liver disease. Evid Based Med: 2008; 13 140
12. Matzno S., Tazuya-Murayama K., Tanaka H., Yasuda S., Mishima M., Uchida T., Nakabayashi T., Matsuyama K. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol: 2003; 55 795 802 (Pubitemid 36752723)
13. Liu Z. L., Liu J. P., Zhang A. L., Wu Q., Ruan Y., Lewith G., Visconte D. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev: 2011; CD008305
14. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y., Wang Z., Si S., Pan H., Wang S., Wu J., Wang Y., Li Z., Liu J., Jiang J. D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med: 2004; 10 1344 1351 (Pubitemid 40022716)
15. Huang X. S., Yang G. F., Pan Y. C. Effect of berberine hydrochloride on blood concentration of cyclosporine A in cardiac transplanted recipients. Chin J Int Tradit West Med: 2008; 28 702 704
16. Moher D., Liberati A., Tetzlaff J., Altman D. G. PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med: 2009; 6 e1000097
17. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J., Gavaghan D. J., McQuay H. J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials: 1996; 17 1 12 (Pubitemid 26120810)
18. Higgins J. PT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0 [updated February 2008]. Chichester The Cochrane Collaboration: 2008
19. Schulz K. F., Chalmers I., Hayes R. J., Altman D. G. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA: 1995; 273 408 412
20. The Nordic Cochrane Centre The Cochrane Collaboration, Review Manager (RevMan). 5.0. Copenhagen The Nordic Cochrane Centre, The Cochrane Collaboration: 2008
21. He J. J., Xu X. G., Zheng S. Therapeutic effects of simvastatin and berberine hydrochloride in the treatment of hyperlipidemia and carotid artery arthrosclerosis. Tianjin Pharm: 2007; 35 539 541
22. Yin S. L., Li C. H., Liu C. M. The effects of berberine hydrochloride on blood glucose, insulin and lipids concentrations in newly diagnosed type 2 diabetic patients. Acta Acad Med Xuzhou: 2011; 31 40 41
23. Kong W. J., Wei J., Zuo Z. Y., Wang Y. M., Song D. Q., You X. F., Zhao L. X., Pan H. N., Jiang J. D. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism: 2008; 57 1029 1037 (Pubitemid 351978060)
24. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., Huo L., Wang M., Hong J., Wu P., Ren G., Ning G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab: 2008; 93 2559 2565 (Pubitemid 352008520)
25. Wei W., Zhao H., Wang A., Sui M., Liang K., Deng H., Ma Y., Zhang Y., Zhang H., Guan Y. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol: 2012; 166 99 105
26. Li Z., Liu L. H. Therapeutic efficacy of combined berberine and glipizide on type 2 diabetes. J Clin Res: 2007; 24 61 64
27. Cao Y. Clinical research on multiple factor intervention of improving the insulin resistance. Jinan Shandong University of Traditional Chinese Medicine: 2007
28. Ju S. B., Tan L. R., Su W., Rong K. W. The intervention of berberine hydrochloride liposomes on impaired glucose tolerance combining with hyperlipidemia. J Pract Tradit Chin Med: 2007; 23 490 491
29. Wang W. Effect of berberine on blood glucose, blood lipid and serum adiponectin of primary type 2 diabetes mellitus patients. Taiyuan Shanxi Medical University: 2008
30. Zheng B. B., Wei J., Jiang J. D., Zhang R. S. The therapeutic effects of combination of simvastatin with berberine on the patients with hyperlipemia. Acta Univ Med Nanjing (Nat Sci): 2009; 29 1493 1497
31. Ye W. P. Clinical efficacy of berberine treatment of diabetes. Mod Hosp: 2010; 10 9 10
32. Zhou Y. F., Huang S. J. Clinical efficacy of berberine in the treatment of 60 patients with hyperlipidemia. Chin J Clin Rat Drug Use: 2011; 4 76 77
33. OBrien K. A. Alternative perspectives: how Chinese medicine understands hypercholesterolemia. Cholesterol: 2010; 2010 723289
34. Xie W., Zhao Y., Du L. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J Ethnopharmacol: 2012; 140 345 367
35. Grundy S. M., Cleeman J. I., Merz N. B., Brewer B., Clark L. T., Hunninghake D. B., Pastemak R. C., Smith S. C. jr., Stone N. J. National Heart, Lung, and Blood Institute American College of Cardiology Foundation American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation: 2004; 110 227 239 (Pubitemid 38924592)
36. Hermann R., von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med: 2012; 78 1458 1477
37. Guo Y., Pope C., Cheng X., Zhou H., Klaassen C. D. Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol: 2011; 138 111 118
38. Guo Y., Chen Y., Tan Z. R., Klaassen C. D., Zhou H. H. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol: 2012; 68 213 217
39. Schulz K. F., Grimes D. A. Blinding in randomised trials: hiding who got what. Lancet: 2002; 359 696 700 (Pubitemid 34203775)
40. Schulz K. F., Grimes D. A. Allocation concealment in randomised trials: defending against deciphering. Lancet: 2002; 359 614 618 (Pubitemid 34178448)